Zenodo
Respiratory Syncytial Virus Vaccine: CDC 19–59 vs 60+ Decision
By Dr. Waleed F. Hassan.
Abstract
CDC guidance for RSV vaccines in adults ages 19–59 versus 60+, including eligibility, dose counts, coverage periods, scheduling, and key constraints. Independent technical note mirroring the canonical version: https://getpulse.care/blog/respiratory-syncytial-virus-vaccine-cdc-1959-vs-60-decision.php
Keywords
- Respiratory viral infections research
- RSV vaccine
- vaccine eligibility
- vaccine dosing
- vaccination scheduling
- CDC guidelines
- Open access
Source
This is a preprint: it has not been peer reviewed yet, and its findings may change.
Published in Zenodo (CERN European Organization for Nuclear Research). The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.